This article is more than 5 years old. Information may no longer be current.
VIDEO: Trial examines PARP inhibitor, checkpoint blockade in advanced pancreatic cancer
Click Here to Manage Email Alerts
CHICAGO — At the ASCO Annual Meeting, HemOnc Today Next Gen Innovator Kim Reiss Binder, MD, assistant professor of medicine at the Hospital of the University of Pennsylvania, discusses an ongoing clinical trial assessing platinum sensitivity as a biomarker of response to a novel treatment combination for advanced pancreatic ductal adenocarcinoma.
The trial includes patients whose disease has not progressed on platinum-based chemotherapy. They will be randomly assigned to treatment with the PARP inhibitor niraparib (Zejula, Tesaro) plus either nivolumab (Opdivo, Bristol-Myers Squibb) or ipilimumab (Yervoy, Bristol-Myers Squibb).
“The reason that we are doing this clinical trial is that we know there is a subpopulation of patients with pancreatic cancer who have a mutation in a gene called BRCA or a gene called PALB2,” she told HemOnc Today. “They do very well with platinum chemotherapy and then also with PARP inhibitors as maintenance… This trial is trying to expand upon that group.”
References:
Binder KAR, et al. Abstract TPS4161. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.
Disclosure: Binder reports receiving institutional funding from Bristol-Myers Squibb, Clovis Oncology, Eli Lilly and Tesaro.